Shanghai Kehua Bio-engineering Co Ltd.
002022
Overview
Corporate Details
- ISIN(s):
- CNE000001KC9
- LEI:
- Country:
- China
- Address:
- N/A
- Website:
- N/A
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Shanghai Kehua Bio-engineering Co Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Shanghai Kehua Bio-engineering Co Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Shanghai Kehua Bio-engineering Co Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX
United States of America
IMMX
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
United States of America
ICCC
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
South Korea
424870
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
United States of America
IBRX
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Japan
4570
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
United States of America
IMCR
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
United States of America
IMNM
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
United States of America
IMRN
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
United States of America
IMNN
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
United States of America
INAB